Dr.GastroMayo said:Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.
This is where I part company with the consensus forming above. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.
wanda_boise said:My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.
Compounded semaglutide formulations for compounded supply: some pharmacies add ingredients like B12, L-carnitine, or BPC-157 to their semaglutide preparations. Are these beneficial or marketing gimmicks?
My take: B12 addition has some logic (GLP-1s can deplete B12). L-carnitine evidence is weak. BPC-157 for GI protection is theoretically interesting but unproven. I prefer straight semaglutide with no additives — fewer variables, cleaner data on what's working.
JessicaH_TX said:A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to.
There is a second half to this that has not been said yet. The trade-off is reversibility against privacy and there is no option that gives you both. Card payments are reversible and disclose the most; crypto discloses least and is irreversible, which is precisely why pressure toward it is a warning sign when it comes from a seller rather than a buyer. Escrow only means anything where the escrow agent is independent of both parties, which is rarely the case in practice.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsFollowing on from DanielChem_CHI — and this may be the naive question:
What actually distinguishes 503A from 503B, in terms of what each may make and from what starting material?
OP back with an update, since a thread like this is useless without one.
The bulks-list asymmetry was the piece I had missed entirely. It explains why one of my two pharmacies is still arguing it can supply and the other simply stopped.